Christine Fu is an accomplished biopharmaceutical expert with a robust blend of scientific rigor and strategic acumen, possessing over 8 years of medical affairs expertise and a comprehensive 12-year tenure in healthcare. Garnering a PhD in Neuroscience from the University of California, San Francisco, and a B.Sc. in Genetics with a minor in Psychology from The University of British Columbia, Fu has cemented their status as a knowledgeable professional in the biotechnology research industry.

Currently serving as Senior Director, Medical Affairs (YESCARTA US Medical Affairs Lead) at Kite Pharma in the San Francisco Bay Area, Fu has demonstrated exceptional ability to drive medical strategy and product launches, notably leading the paradigm-shifting launch in second-line LBCL (ZUMA-7). With a deep understanding of oncology, including immunotherapy and small molecule drugs across hematological malignancies and solid tumors, Fu has built strong, collaborative relationships with both KOLs and stakeholders while effectively partaking in evidence generation, resulting in co-authorship on multiple manuscripts and abstracts.

Fu's career showcases a history of leadership roles, each marked with significant achievements like successfully pivoting medical strategies during the pandemic and spearheading the medical affairs activities for CAR T-cell therapies TECARTUS, not to mention their instrumental role in launching LUMAKRAS, a first-in-class KRAS G12C inhibitor in NSCLC. With an exceptional LinkedIn network of 1845+ connections, Fu's communication and collaboration skills are as impressive as the scientific contributions they've made, which includes a patent publication for technology in circulating tumor cell enrichment.